ペルジェタ（ペルツズマブ）の世界市場レポート 2025年：疫学、パイプライン分析、市場インサイトと予測

ペルジェタ（ペルツズマブ）の市場規模は今後数年で急成長が見込まれます。2029年にはCAGR16%で19億3,270万米ドルに成長します。予測期間の成長は、乳がん罹患率の上昇、血液悪性腫瘍に対するADCへの関心の高まり、がん罹患率の上昇とアンメット・メディカル・ニーズの高まり、がん免疫療法に対する医薬品の研究開発の増加に起因すると考えられます。予測期間における主要動向としては、がん領域におけるバイオシミラーの採用、バイオシミラーとジェネリック医薬品の開発、薬剤製剤の革新、がん免疫療法研究の進展、併用療法の台頭などが挙げられます。

乳がん罹患率の上昇がペルジェタ（ペルツズマブ）市場の成長を牽引すると予想されます。乳がんは乳腺組織に悪性細胞が発生する疾患で、乳管や小葉に発生することが多いです。乳がん患者の増加は、肥満率の増加や座りがちな生活習慣などのライフスタイルの変化や、広範な検診プログラムによる早期発見の改善などの要因によるものです。ペルジェタ（ペルツズマブ）は、HER2受容体を標的としたHER2陽性乳がんの治療に使用され、通常、治療成績を高めるためにトラスツズマブや化学療法と併用されます。例えば、2023年10月、英国を拠点とする慈善団体Ray of Light Walesは、英国で乳がんと診断された後に生活する人の数は、2023年の60万人から2030年には120万人に倍増すると予測されると報告しました。従って、乳がん罹患率の上昇がペルジェタ市場の成長を牽引しています。

ペルジェタ（ペルツズマブ）市場の主要動向は、患者の予後と治療の利便性を改善するために、皮下併用療法などの技術的に先進的なソリューションの開発に注力していることです。皮下注併用療法は、1回の皮下注射で2種類以上の薬剤を組み合わせて特定の病態を治療するものです。2023年11月、日本の製薬会社である中外製薬株式会社は、HER2陽性乳がんと進行・再発HER2陽性大腸がんの皮下併用療法であるPhesgoを発売しました。この画期的な治療は、ペルツズマブとトラスツズマブにボルヒアルロニダーゼアルファを配合したもので、わずか5～8分で投与が可能となり、従来型点滴静注に比べ投与時間を大幅に短縮することができます。Phesgoは、HER2陽性大腸がんに対する初の皮下投与オプションであり、治療デリバリーにおける大きな進歩を示すものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 バイオ医薬品市場における製品特性

• 分子タイプ
• 投与経路（ROA）
• 作用機序（MOA）
• 安全性と有効性

第4章 市場動向と戦略

第5章 市場-マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症、景気回復が市場に与える影響を含むマクロ経済シナリオ

第6章 世界の成長分析と戦略分析フレームワーク

• 世界のペルジェタ（ペルツズマブ）：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のペルジェタ（ペルツズマブ）市場：成長率分析
• 世界のペルジェタ（ペルツズマブ）市場の実績：規模と成長、2019～2024年
• 世界のペルジェタ（ペルツズマブ）市場の予測：規模と成長、2024～2029年、2034年
• 世界のペルジェタ（ペルツズマブ）：総潜在市場規模（TAM）

第7章 世界市場の価格分析と予測

第8章 市場セグメンテーション

• 世界のペルジェタ（ペルツズマブ）市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 人間由来
• 動物由来
• 世界のペルジェタ（ペルツズマブ）市場：製品別、実績と予測、2019～2024年、2024～2029年、2034年
• モノクローナル抗体
• 生物製剤
• 世界のペルジェタ（ペルツズマブ）市場：適応症別、実績と予測、2019～2024年、2024～2029年、2034年
• 早期乳がん
• 転移性乳がん
• 世界のペルジェタ（ペルツズマブ）市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン薬局

第9章 臨床適応症の世界市場疫学

• 薬剤の副作用
• 臨床適応症の発症率と有病率

第10章 地域別・国別分析

• 世界のペルジェタ（ペルツズマブ）市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のペルジェタ（ペルツズマブ）市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第11章 アジア太平洋市場

第12章 中国市場

第13章 インド市場

第14章 日本市場

第15章 オーストラリア市場

第16章 韓国市場

第17章 西欧市場

第18章 英国市場

第19章 ドイツ市場

第20章 フランス市場

第21章 東欧市場

第22章 北米市場

第23章 米国市場

第24章 カナダ市場

第25章 南米市場

第26章 中東市場

第27章 アフリカ市場

第28章 競合情勢と企業プロファイル

• ペルジェタ（ペルツズマブ）市場：競合情勢
• ペルジェタ（ペルツズマブ）市場：企業プロファイル
  • Roche Holding AG

第29章 世界市場：パイプライン分析

第30章 世界の市場競合ベンチマーキングとダッシュボード

第31章 主要な合併と買収

第32章 最近の市場動向

第33章 市場の潜在力が高い国、戦略

• ペルジェタ（ペルツズマブ）市場、2029年：新たな機会を提供する国
• ペルジェタ（ペルツズマブ）市場、2029年：新たな機会を提供するセグメント
• ペルジェタ（ペルツズマブ）市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第34章 付録

Perjeta (pertuzumab) is a targeted therapy used in the treatment of specific types of breast cancer. It is a monoclonal antibody that binds to the human epidermal growth factor receptor 2 (HER2), a protein that accelerates the growth of cancer cells in HER2-positive breast cancer.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary types of perjeta (pertuzumab) are human source and animal source. While Perjeta is a monoclonal antibody developed through recombinant DNA technology and produced using mammalian cell lines, animal-derived components may be used in the production process. It includes products like monoclonal antibodies and biologic drugs, with indications for conditions such as early-stage and metastatic breast cancer. Perjeta is distributed through multiple channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The perjeta (pertuzumab) market research report is one of a series of new reports from The Business Research Company that provides perjeta (pertuzumab) market statistics, including perjeta (pertuzumab) industry global market size, regional shares, competitors with a perjeta (pertuzumab) market share, detailed perjeta (pertuzumab) market segments, market trends and opportunities, and any further data you may need to thrive in the perjeta (pertuzumab) industry. This perjeta (pertuzumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The perjeta (pertuzumab) market size is expected to see rapid growth in the next few years. It will grow to $1,932.7 million in 2029 at a compound annual growth rate (CAGR) of 16%. The growth in the forecast period can be attributed to the rising incidence of breast cancer, rising interest in ADCs for hematologic malignancies, rising incidence of cancer, rising cancer incidence and unmet medical needs, and increasing pharmaceutical R&D for cancer immunotherapy. Major trends in the forecast period include the adoption of biosimilars in oncology, the development of biosimilars and generics, innovation in drug formulations, advances in cancer immunotherapy research, and combination therapies gaining prominence.

The rising incidence of breast cancer is expected to drive the growth of the perjeta (pertuzumab) market. Breast cancer is a disease where malignant cells develop in breast tissue, often originating in the ducts or lobules. The increase in breast cancer cases is attributed to factors like lifestyle changes, such as higher obesity rates and sedentary habits, along with improvements in early detection through widespread screening programs. Perjeta (pertuzumab) is used to treat HER2-positive breast cancer by targeting the HER2 receptor and is typically combined with trastuzumab and chemotherapy for enhanced treatment outcomes. For example, in October 2023, the Ray of Light Wales, a UK-based charity, reported that the number of people living after a breast cancer diagnosis in the UK is projected to double from 600,000 in 2023 to 1.2 million by 2030. Therefore, the rising incidence of breast cancer is driving the growth of the perjeta market.

A key trend in the perjeta (pertuzumab) market is the focus on developing technologically advanced solutions, such as subcutaneous combination therapies, to improve patient outcomes and treatment convenience. Subcutaneous combination therapies involve the combination of two or more drugs in a single subcutaneous injection to treat a specific condition. In November 2023, Chugai Pharmaceutical Co., Ltd., a Japan-based pharmaceutical company, launched Phesgo, a subcutaneous combination treatment for HER2-positive breast cancer and advanced or recurrent HER2-positive colorectal cancer. This innovative treatment combines pertuzumab and trastuzumab with vorhyaluronidase alfa, allowing administration in just 5 to 8 minutes, significantly reducing time compared to traditional intravenous infusions. Phesgo is the first subcutaneous option for HER2-positive colorectal cancer, marking a major advancement in treatment delivery.

In June 2024, Zydus Pharmaceuticals, an India-based company, partnered with Dr. Reddy's Laboratories to enhance access to a pertuzumab biosimilar for HER2-positive breast cancer patients in India. This collaboration aims to improve the affordability, availability, and patient outcomes by leveraging their combined distribution efforts. Dr. Reddy's Laboratories, a key player in the Indian pharmaceutical sector, offers pertuzumab biosimilars, making this partnership a significant step toward increasing the accessibility of this treatment in the region.

Key player operating in the perjeta (pertuzumab) market is Roche Holding AG.

North America was the largest region in the perjeta (pertuzumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in perjeta (pertuzumab) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the perjeta (pertuzumab) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The perjeta (pertuzumab) market consists of sales of products including herceptin, docetaxel, paclitaxel, and carboplatin. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Perjeta (Pertuzumab) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on perjeta (pertuzumab) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for perjeta (pertuzumab) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The perjeta (pertuzumab) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Human source; Animal source
• 2) By Product: Monoclonal Antibody; Biologic Drug
• 3) By Indication: Early Breast Cancer; Metastatic Breast Cancer
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Companies Mentioned: Roche Holding AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Perjeta (Pertuzumab) Market Characteristics

3. Perjeta (Pertuzumab) Market Biologic Drug Characteristics

• 3.1. Molecule Type
• 3.2. Route Of Administration (ROA)
• 3.3. Mechanism Of Action (MOA)
• 3.4. Safety And Efficacy

4. Perjeta (Pertuzumab) Market Trends And Strategies

5. Perjeta (Pertuzumab) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

6. Global Perjeta (Pertuzumab) Growth Analysis And Strategic Analysis Framework

• 6.1. Global Perjeta (Pertuzumab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 6.2. Analysis Of End Use Industries
• 6.3. Global Perjeta (Pertuzumab) Market Growth Rate Analysis
• 6.4. Global Perjeta (Pertuzumab) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 6.5. Global Perjeta (Pertuzumab) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 6.6. Global Perjeta (Pertuzumab) Total Addressable Market (TAM)

7. Global Perjeta (Pertuzumab) Market Pricing Analysis & Forecasts

8. Perjeta (Pertuzumab) Market Segmentation

• 8.1. Global Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Human source
• Animal source
• 8.2. Global Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibody
• Biologic Drug
• 8.3. Global Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Early Breast Cancer
• Metastatic Breast Cancer
• 8.4. Global Perjeta (Pertuzumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

9. Global Perjeta (Pertuzumab) Market Epidemiology Of Clinical Indications

• 9.1. Drug Side Effects
• 9.2. Incidence And Prevalence of Clinical Indications

10. Perjeta (Pertuzumab) Market Regional And Country Analysis

• 10.1. Global Perjeta (Pertuzumab) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. Global Perjeta (Pertuzumab) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Asia-Pacific Perjeta (Pertuzumab) Market

• 11.1. Asia-Pacific Perjeta (Pertuzumab) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Asia-Pacific Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Asia-Pacific Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. China Perjeta (Pertuzumab) Market

• 12.1. China Perjeta (Pertuzumab) Market Overview
• 12.2. China Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.3. China Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.4. China Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

13. India Perjeta (Pertuzumab) Market

• 13.1. India Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. India Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. India Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. Japan Perjeta (Pertuzumab) Market

• 14.1. Japan Perjeta (Pertuzumab) Market Overview
• 14.2. Japan Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. Japan Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. Japan Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Australia Perjeta (Pertuzumab) Market

• 15.1. Australia Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.2. Australia Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Australia Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. South Korea Perjeta (Pertuzumab) Market

• 16.1. South Korea Perjeta (Pertuzumab) Market Overview
• 16.2. South Korea Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. South Korea Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.4. South Korea Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Western Europe Perjeta (Pertuzumab) Market

• 17.1. Western Europe Perjeta (Pertuzumab) Market Overview
• 17.2. Western Europe Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Western Europe Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.4. Western Europe Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. UK Perjeta (Pertuzumab) Market

• 18.1. UK Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. UK Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. UK Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Germany Perjeta (Pertuzumab) Market

• 19.1. Germany Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Germany Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Germany Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. France Perjeta (Pertuzumab) Market

• 20.1. France Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. France Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. France Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Perjeta (Pertuzumab) Market

• 21.1. Eastern Europe Perjeta (Pertuzumab) Market Overview
• 21.2. Eastern Europe Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. North America Perjeta (Pertuzumab) Market

• 22.1. North America Perjeta (Pertuzumab) Market Overview
• 22.2. North America Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. North America Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.4. North America Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. USA Perjeta (Pertuzumab) Market

• 23.1. USA Perjeta (Pertuzumab) Market Overview
• 23.2. USA Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. USA Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. USA Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. Canada Perjeta (Pertuzumab) Market

• 24.1. Canada Perjeta (Pertuzumab) Market Overview
• 24.2. Canada Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. Canada Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. Canada Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. South America Perjeta (Pertuzumab) Market

• 25.1. South America Perjeta (Pertuzumab) Market Overview
• 25.2. South America Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. South America Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. South America Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. Middle East Perjeta (Pertuzumab) Market

• 26.1. Middle East Perjeta (Pertuzumab) Market Overview
• 26.2. Middle East Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. Middle East Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. Middle East Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Africa Perjeta (Pertuzumab) Market

• 27.1. Africa Perjeta (Pertuzumab) Market Overview
• 27.2. Africa Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Africa Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.4. Africa Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Perjeta (Pertuzumab) Market Competitive Landscape And Company Profiles

• 28.1. Perjeta (Pertuzumab) Market Competitive Landscape
• 28.2. Perjeta (Pertuzumab) Market Company Profiles
  • 28.2.1. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis

29. Global Perjeta (Pertuzumab) Market Pipeline Analysis

• 29.1. High Level Clinic Trail Information

30. Global Perjeta (Pertuzumab) Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Perjeta (Pertuzumab) Market

32. Recent Developments In The Perjeta (Pertuzumab) Market

33. Perjeta (Pertuzumab) Market High Potential Countries, Segments and Strategies

• 33.1 Perjeta (Pertuzumab) Market In 2029 - Countries Offering Most New Opportunities
• 33.2 Perjeta (Pertuzumab) Market In 2029 - Segments Offering Most New Opportunities
• 33.3 Perjeta (Pertuzumab) Market In 2029 - Growth Strategies
  • 33.3.1 Market Trend Based Strategies
  • 33.3.2 Competitor Strategies

34. Appendix

• 34.1. Abbreviations
• 34.2. Currencies
• 34.3. Historic And Forecast Inflation Rates
• 34.4. Research Inquiries
• 34.5. The Business Research Company
• 34.6. Copyright And Disclaimer